Muscle-growth booster peptide (myostatin prodomain minimum peptide 1)
A small lab-made peptide that blocks myostatin, the body's natural brake on muscle size, potentially helping treat muscle-wasting diseases, experimental, not yet an approved drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Myostatin prodomain minimum peptide (also called "peptide 1" in the Takayama 2015 series) is a 23-amino acid synthetic peptide corresponding to positions 21–43 of the mouse myostatin prodomain. It is the shortest fragment of that prodomain that retains measurable inhibitory activity against myostatin — the protein responsible for capping skeletal muscle growth in mammals. Myostatin (also known as GDF-8, Growth Differentiation Factor 8) is produced by muscle and acts on muscle to limit how large it can grow; animals and rare humans who lack functional myostatin develop striking muscle hypertrophy. This peptide mimics the α-helical region of the natural prodomain that contacts myostatin and prevents it from engaging its receptor complex. The stored sequence WRQNTRYSRIEAIKIQILSKLRL is a mouse-derived, unmodified free-acid peptide — unlike the endogenous prodomain, it carries no N-glycosylation and is not amidated at the C-terminus. It has no approved clinical use and has not entered human trials.
History
Myostatin was identified in 1997 by McPherron, Lawler, and Lee at Johns Hopkins as a new TGF-β superfamily member whose knockout in mice produced roughly doubled skeletal muscle mass. "Double-muscled" cattle breeds (Belgian Blue, Piedmontese) were soon traced to natural myostatin loss-of-function variants, and a human infant with a myostatin null mutation showing extraordinary muscle mass was reported in 2004 (Schuelke and colleagues, NEJM). These observations established myostatin as a validated drug target for muscle-wasting diseases.
Myostatin is secreted as a latent complex: after signal peptide cleavage and furin processing, the N-terminal prodomain remains non-covalently associated with the mature C-terminal dimer, physically occluding the surfaces that bind the ActRIIB receptor. BMP-1 and Tolloid metalloproteinases cleave the prodomain to liberate active myostatin. This endogenous inhibitory architecture — the prodomain acting as a latency-associated peptide — motivated the synthetic minimum-peptide approach: if the α-helical core of the prodomain does the blocking, what is the shortest sequence that still inhibits?
The answer was worked out by Takayama, Asari, and colleagues in Japan (Osaka University and the National Center of Neurology and Psychiatry) through a systematic truncation program published between 2015 and 2019. The 23-residue "peptide 1" (pep-10785) was defined by Takayama and colleagues (2015) as the minimum inhibitory core — the threshold between measurable and undetectable activity in cell-based assays. Subsequent SAR work in the same group applied hydrophobic-residue substitutions and chain shortening to improve potency, producing analogs with IC50 values roughly ten-fold lower and, eventually, demonstrable grip-strength improvement in mouse models (Takayama and colleagues, 2019).
What it does
The peptide blocks myostatin signaling by mimicking the inhibitory α-helix of the natural prodomain. It positions itself between myostatin and the type II receptor (ActRIIB), preventing assembly of the ActRIIB/ALK4–ALK5 type I/II receptor complex that propagates the Smad2/3 transcriptional signal that suppresses muscle growth genes.
In HEK293 cell-based luciferase reporter assays driven by a SMAD-responsive element, it reduces myostatin-induced signal with an IC50 of approximately 10 µM (Takayama and colleagues, 2015). This is substantially weaker than the full prodomain (approximately 1 nM range), because the 23-aa fragment captures only the α-helical core of the multi-contact prodomain interaction.
CD spectroscopy confirmed that the peptide adopts a predominantly α-helical conformation in solution (Takayama and colleagues, 2015). Alanine-scanning across the 23 residues established that hydrophobic residues on one face of the helix drive binding to a complementary groove on the myostatin dimer surface; sequence changes that disrupt the helix or eliminate the hydrophobic contacts abolish activity (Takayama and colleagues, 2015). The helix is the pharmacophore, not any individual short motif within it.
Structure-guided analysis by Asari and colleagues (2017) used NMR and MD simulation to characterize the helical binding geometry and identify positions where hydrophobic substitutions improved IC50 toward the 1 µM range for first-generation optimized analogs.
Evidence
- Human: No human trials have been conducted with the minimum peptide or its direct analogs. The clinical myostatin inhibitor field is dominated by monoclonal antibodies and ActRIIB-Fc fusion proteins (bimagrumab, apitegromab, landogrozumab), not prodomain-mimetic peptides.
- Animal: Chain-shortened analogs derived from this minimum peptide series — optimized through the hydrophobic substitution program begun at pep-10785 — significantly improved forelimb grip strength in normal mice after subcutaneous administration over two weeks, providing in vivo proof-of-concept for the prodomain-mimetic approach (Takayama and colleagues, 2019). The parent minimum peptide itself has not been tested in grip-strength assays; the in vivo data apply to later analogs in the same series.
- In vitro: The minimum peptide inhibits human myostatin in HEK293 SMAD-luciferase reporter assays (IC50 ~10 µM) and blocks assembly of the ActRIIB/ALK4–ALK5 receptor complex (Takayama and colleagues, 2015). Structural characterization confirmed the α-helical binding mode and identified key hydrophobic residues required for activity (Asari and colleagues, 2017; Takayama and colleagues, 2017).
Known effects
- Myostatin signaling inhibition (in vitro) — IC50 ~10 µM in HEK293 SMAD-luciferase assay; mechanistic only
- ActRIIB/ALK4–5 receptor complex disruption (in vitro) — confirmed contact displacement; mechanistic only
- α-Helical structure required for activity — demonstrated by CD spectroscopy and alanine scanning; mechanistic only
- In vivo muscle functional effect (chain-shortened analogs) — grip strength improvement in mice; preclinical
Myths and misconceptions
- "The minimum peptide is equivalent to the full myostatin prodomain." It is not. The 23-aa minimum peptide has an IC50 of approximately 10 µM against human myostatin; the full prodomain operates at roughly 1 nM — a difference of approximately 1,000-fold. The prodomain inhibits through a multivalent interaction spanning much of the growth factor surface; the minimum peptide captures only the α-helical core of that contact. The two are related in mechanism but should not be treated as pharmacological equivalents.
- "Clinical myostatin inhibitor failures mean this peptide approach won't work either." The large-biologic failures (ACE-031 halted for bleeding and telangiectasia; stamulumab and domagrozumab showing disappointing endpoints in DMD) reflect the challenges of broad TGF-β pathway disruption and antibody pharmacology, not specifically the prodomain-mimetic small-peptide approach. The minimum-peptide series is exploring a different pharmacological format — short synthetic peptide, not biologic — with the distinct advantages and liabilities that come with that.
- "This peptide is a bodybuilding compound." The peptide has an IC50 in the micromolar range, requires parenteral administration, and has only preclinical data (and only for optimized analogs, not the parent compound). It is a medicinal chemistry research probe for defining the pharmacophore of a therapeutic class addressing muscle-wasting diseases, not a practical muscle enhancement agent.
Common questions
What is the therapeutic rationale for myostatin inhibitor development? Myostatin is expressed by skeletal muscle and acts locally to limit muscle growth. In disease states characterized by progressive muscle loss — Duchenne muscular dystrophy, spinal muscular atrophy, cancer cachexia, sarcopenia — blocking myostatin is hypothesized to preserve or restore functional muscle mass. The prodomain minimum peptide series provides a medicinal chemistry starting point for small synthetic inhibitors that could eventually be optimized for stability, potency, and delivery in such conditions.
How does this peptide differ from follistatin-based myostatin inhibitors? Follistatin is a separate glycoprotein that wraps around the myostatin dimer and sequesters it in a high-affinity complex through a different binding geometry than the prodomain. A follistatin-derived minimum peptide approach (DF-3, derived from follistatin residues 41–54) was developed in parallel by the same research group (Saitoh and colleagues, 2020). The prodomain approach (pep-10785) targets the receptor-binding face of myostatin from the prodomain side; the follistatin approach targets overlapping but distinct surfaces. See DF-3 for the follistatin-loop inhibitor from the same research lineage.
How potent is this peptide compared to later analogs in the series? The minimum peptide (pep-10785, IC50 ~10 µM) is the least-potent member of the series by design — it establishes the minimum pharmacophore. Hydrophobic substitutions at key helix positions, reported by Takayama and colleagues (2017), improved IC50 to approximately 1 µM for the best first-generation analogs (Asari and colleagues, 2017). Chain-shortened variants further refined the series, with in vivo activity demonstrated in the 2019 work (Takayama and colleagues, 2019). The minimum peptide's value is historical and pharmacophoric, not as the lead compound.
Related peptides
- DF-3 (pep-00127) — follistatin-derived myostatin inhibitory peptide; minimum inhibitory core of the follistatin N-terminal domain (residues 41–54), developed by the same research group in parallel; different sequence origin and binding geometry but same target (myostatin/GDF-8) and same in vitro assay format (HEK293 SMAD-luciferase)
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does this peptide accidentally interfere with a closely related protein that controls heart and brain health?
Knowing this early could prevent unexpected side effects in patients and guide chemists to redesign the peptide so it only affects muscle. It would also reveal whether the peptide could be repurposed for heart or brain conditions.
Could blocking the same protein that limits muscle growth also help a weakened heart recover?
Heart failure is one of the leading causes of death worldwide and few drugs address the underlying muscle loss in the heart. If this peptide works there too, it could open a new treatment avenue for millions of patients using chemistry that is already partly understood.
Is it the back half of the peptide, not the full sequence, that blocks the muscle-growth limiter?
If true, a much shorter, cheaper version of this peptide could be designed to treat muscle-wasting diseases. This could lower the cost and complexity of developing treatments for conditions like muscular dystrophy or age-related muscle loss.
Could this peptide stop the internal scarring in muscles, not just help them grow bigger?
Duchenne muscular dystrophy kills through scarring of the heart and breathing muscles, which current gene therapies do not fully address. If this peptide reduces that scarring, it could meaningfully extend survival and quality of life for boys with the disease.
Could attaching a small fat-like molecule to this peptide make it work longer inside the body?
If correct, patients with muscle-wasting conditions might only need a once-a-week injection rather than daily treatment. This approach uses chemistry already proven safe in diabetes drugs, reducing the risk of unexpected side effects.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.5373983383178711 | boltz-2 |
| ranking score | 0.7026341557502747 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | colabfold_local |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-22 |
▸citationbibtex
@peptide{pep10785,
sequence = {WRQNTRYSRIEAIKIQILSKLRL},
target = {gdf-8},
author = {peptidemodel},
year = {2026},
status = {synthesized}
}